The seven-transmembrane (7TM) G-protein-coupled neuroendocrine receptors VPAC1 (HGNC approved gene symbol VIPR1) and VPAC2 (HGNC approved gene symbol VIPR2) are expressed in different tissues and involved in the regulation of important biological functions. We now report the identification and characterization of novel five-transmembrane(5TM) forms of both human VPAC1 and human VPAC2. These alternatively spliced variant mRNAs result from the skipping of exons 10/11, spanning the third intracellular loop, the fourth extracellular loop, and the transmembrane regions 6 and 7, producing in-frame 5TM receptors predicted to lack a G-protein-binding motif. RT-PCR showed that these 5TM receptors are differentially expressed in transformed and normal cells. Translation of the 5TM protein was demonstrated by transfection and expression in CHO cells. Following agonist stimulation, differential signaling of the 7TM versus 5TM forms was shown both for the activation of adenylate cyclase and for tyrosine phosphorylation. The identification of these splice variants in various cells and their expression and differential signal transduction compared to the 7TM form suggest that these novel receptors have biological relevance.
The human vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptor family consists of three receptors, PAC1 (HGNC approved gene symbol ADCYAP1R1), VPAC1, and VPAC2 [1, 2] . These receptors belong to the class II subfamily of the seventransmembrane (7TM) G-protein-coupled receptor (GPCR) superfamily [1, 2] . VPAC1 was first cloned from a rat lung cDNA library by cross-hybridization with a secretin receptor [3] . The human VPAC1 cDNA was first characterized from the HT29 human colonic adenocarcinoma cell line library [4] . The VPAC1 receptor comprises 457 amino acids and its gene spans 22 kb, which is composed of 13 exons ranging in size from 42 to 1400 bp [4] . VPAC1 is evolutionarily conserved and structurally characterized by its 7TM domains with an extracellular N-terminus and a cytoplasmic C-terminus [5] . VPAC1 is found in certain regions of the brain, notably the piriform cortex, the septal nucleus, and the hippocampal formation [6, 7] . VPAC1 is also a predominant receptor expressed on other cells and tissues, particularly on resting T lymphocytes and peripheral blood monocytes [8] [9] [10] . In addition, studies have shown that tumor-derived breast and intestinal cell lines, as well as some malignant T lymphoblastic cell lines, exhibit VPAC1 mRNA in large amounts [10] [11] [12] . Furthermore, our laboratory has recently shown that VPAC1 binds to human immunodeficiency virus type 1 (HIV-1) to transduce an intracellular signal that results in facilitation of HIV-1 productive infection [13] .
The VPAC2 receptor was initially cloned from a rat pituitary cDNA library [14] and subsequently from a human placenta cDNA library [15] . VPAC2 is present in human skeletal muscle, intestine, and brain, especially in the thalamus and cerebral cortex [16, 17] . VPAC2 is encoded by 13 exons and the human gene spans 117 kb [15] . VPAC2 is expressed more selectively than is VPAC1. VPAC2 is found at very low levels on resting monocytes and T cells but its expression is increased after activation of these cells [10] .
Significant differences exist between VPAC1 and VPAC2, both in structure and in function [18, 19] . Indeed, there are a number of reports indicating opposing functions for these two receptors [20, 21] . Recently, we have shown that VPAC2 stimulation by specific agonists dramatically inhibits HIV-1 productive infection [22] . The opposite effect is observed after VPAC1 stimulation, which causes an increase in HIV-1 productive infection [13] .
In this study, we describe the identification, isolation, and characterization of two novel human 5TM VPAC receptor isoforms, one of VPAC1 and one of VPAC2. This is the first description of these isoforms in human cells. These splicevariant VPAC isoforms are differentially expressed in normal human primary peripheral blood mononuclear and cord blood cells and in malignant hematopoietic-and epithelial-derived cancer cell lines. Using transfection, we confirmed that the 5TM isoform, predicted by sequence analysis to lack a G-proteinbinding site, can be translated and has significantly decreased ability to increase intracellular cAMP in response to vasoactive intestinal peptide (VIP) and secretin compared to cells transfected to express the 7TM receptor. However, despite a lack of G protein binding and adenylate cyclase activation, stimulation of the 5TM isoform was, nonetheless, able to activate protein tyrosine kinase activity that showed a differential pattern of resulting phosphotyrosine-containing proteins compared to the 7TM receptor. These results suggest that both isoforms of VPAC1 and VPAC2 would have biological relevance.
Results

Sequence alignment of VPAC1 and VPAC2 isoforms
In our effort to clone full-length human VPAC1 from normal peripheral blood mononuclear cells (PBMCs) and VPAC2 from the human Sup-T1 cell line, we unexpectedly identified splice variant receptor transcripts. These variant receptors of VPAC1 and VPAC2, bearing 264-and 222-bp deletions, respectively, showed an open reading frame that would encode receptors lacking, respectively, 88 and 74 amino acid residues (Fig. 1) . Interestingly, analysis of the deduced amino acid sequences revealed that the truncated VPAC1 and VPAC2 isoforms lack the regions in the third intracellular loop, the fourth extracellular loop, and TM6-7 (Figs. 1 and 2A). These alternative splicing events result in transcripts that encode a putative five-transmembrane domain form (Fig. 2B ).
VPAC1 and VPAC2 expression in normal and malignant cells
It has been reported that 7TM VPAC1 and VPAC2 are, or can be induced to be, expressed in most human tissues [23, 24] . As the identification of human 5TM isoforms has never been reported, we examined the expression of 7TM compared to 5TM VPAC1 and VPAC2 isoforms in different cells. A strategy using specific primers designed to amplify both 5TM and 7TM VPAC1 isoforms (Fig. 3A) was confirmed using Hut78 cells (Fig. 3B ). Using this RT-PCR demonstrated differential patterns of mRNA expression in different cells. In normal, nonactivated PBMCs, and malignant cell lines Hut78, Raji, and Colo205, expression of both isoforms was evident. However, in normal cord blood PBMCs and malignant CaCo2 and transformed 293 cells, only the 7TM form of VPAC1 was found. Furthermore, the T cell leukemia-derived Kit225 and ACHN kidney-derived cells do not express either VPAC1 isoform.
A strategy using nested RT-PCR (Fig. 4A ) was optimized and used to examine the expression of 5TM and 7TM VPAC2 receptor isoforms. The ability of the RT-PCR to amplify both transcripts was confirmed using Sup-T1 cells (Fig. 4B) . The results reveal limited expression of the 5TM isoform but also differential expression of the VPAC2 mRNA (Fig. 4C ). Normal nonactivated PBMCs express low levels of 7TM VPAC2 mRNA as previously published [9, 10] ; however, these cells do not express the 5TM isoform (Fig. 4C ). Following activation with PHA/IL-2 or with PHA alone, the 7TM isoform of VPAC2 shows increased expression and the 5TM isoform is now also expressed; indeed, the only other cells tested that expressed 5TM VPAC2 transcripts were Sup-T1 cells, the original cells from which the two isoforms were cloned. Neither Daudi nor THP-1 cells express either transcript. The other cell lines examined expressed only the 7TM VPAC2. These results were confirmed by Southern blot, which showed hybridization of a full-length VPAC2 radioactive probe to only those bands corresponding to the 5TM and 7TM positive (+ve) controls (Fig. 4D) . 
Protein expression of 5TM isoform
Because it has been reported that certain mutations in the GPCR may result in poor protein expression and/or impair the stability of the receptor on the membrane [25, 26] , it is important to show that the novel alternative splicing we have documented results in protein production. Due to a lack of potent antibodies to VPAC receptors, to address this issue, we used transfection of CHO cells with VPAC1 5TM and 7TM cDNA in pcDNA3.1, which contains an Xpress tag so as to be able to monitor the protein expression by immunoprecipitation of metabolically labeled protein. Fig. 5 shows our results that indicate the translation of these isoforms to the predicted molecular sized proteins and support previous reports of production of other cell surface proteins having mutations encoding a truncated receptor [27, 28] .
Functionality of VPAC isoforms
GPCR responses are critically dependent on the functional interaction between the receptor and its ligand and the subsequent G-protein-dependent activation. These interactions lead to the generation of a signaling pathway(s) that ultimately leads to a specific cell function. To examine whether 5TM VPAC isoforms retain functionality, particularly as they are predicted by sequence analyses to lack a G-protein-binding site, we compared the abilities of the 7TM and 5TM isoforms to induce increased production of cAMP and also examined their ability to activate tyrosine kinases. The response to VIP caused an approximately fourfold increase in cAMP production in transfected CHO cells with 7TM VPAC1 compared to emptyvector control. Response to VIP by 5TM-transfected cells did not result in an increase in cAMP (Fig. 6A) . Receptor-mediated cellular responses to secretin were also tested and revealed results similar to those obtained for VIP (Fig. 6A) .
A series of experiments was next performed to evaluate tyrosine kinase activation following VIP or secretin stimulation of 7TM and 5TM VPAC1 isoforms. In this regard, transfected CHO cells were serum starved overnight and then stimulated with 50 μM VIP or secretin for 30 min at 37°C. Cells were washed with PBS and lysed in radioimmunoprecipitation assay (RIPA) lysis buffer. Although no differences in phosphorylation between the 5TM-and the 7TM-transfected cells was apparent after stimulation with VIP for 30 min, both showed increased phosphorylation after stimulation compared to empty vector control. The lack of differential tyrosine phosphorylation may be due to some cross-reactivity of the VIP with endogenous VPAC2 on these cells. In contrast to stimulation with VIP, Western blot analysis of phosphotyrosine-containing proteins after 30 min stimulation with secretin showed differential tyrosine kinase activation (Fig. 6B) . Proteins of approximately 50 and 60 kDa showed no increased phosphorylation after secretin stimulation in the 5TM-compared to the 7TM-transfected cells, while proteins of approximate molecular sizes of 30 and 38 kDa showed increased phosphorylation compared to 7TM-transfected cells. Although the identity of these phosphorylated proteins remains to be determined, it can be speculated that these differences in tyrosine phosphorylation may lead to generation of a different signaling pathway(s) and that this differential tyrosine phosphorylation may lead to unique cell activity or function. Further investigations are necessary to elucidate the specific signaling pathways following activation of the different VPAC receptor isoforms.
Discussion
Different isoforms of GPCR have been previously identified for a number of receptors. In one report, identification and characterization of a 5TM domain variant isoform of the NTS2 neurotensin receptor in the rat central nervous system was described [29] . These investigators demonstrated that alternative splicing of the rat NTS2 receptor gene generated a 5TM domain variant (vNTS2) that is coexpressed with the full-length NTS2 receptor throughout the brain and spinal cord. These findings suggested that the rat vNTS2 is a functional receptor that may play a role in NT signaling in the mammalian central nervous system. In another study, 5TM mutants of the chemokine receptors CCR5 and CXCR4 were reported [30] . It was found that 5TM isoforms were produced by the Nterminal segment connecting directly to TM3 as a result of a deletion of TM1-2 and the first intracellular and extracellular loops. In this study it was also shown that the 5TM CCR5 and CXCR4 isoforms functioned as normal chemokine receptors in mediating different cell function [30] . It was concluded that in the case of CCR5 and CXCR4, 5TM isoforms appear to meet the minimum structural requirements for a functional GPCR. Importantly, investigators have previously reported splice variants of the VPAC family member receptor PAC1 [31] [32] [33] . In one report [31] , splice variants of PAC1 that exhibited altered adenylate cyclase stimulation and differential abundance were identified in the frog. In another study [32] , Chaudhary and Baumann found PAC1 splice variants, but not VPAC2 variants, in the rat brain. Stimulation of the PAC1 variants with PACAP indicated similar potency of these variant receptors. However, in a recent study [33] , variants of PAC1 were found in human neuroblastoma cells that demonstrated differential signaling and the authors concluded that the variant PAC1 receptors have an important role in the developing nervous system.
Although there have not been any reports until our work of splice variants of human VPAC1 or VPAC2, an isoform of the VPAC2 receptor has been previously described in mouse [34] . This VPAC2 receptor isoform was identified in immune cells and shown to have a deletion in the carboxyl-terminal end of the seventh transmembrane domain. These investigators also showed that wild-type and the deletion variant VPAC2 bound the same amount of 125 I-VIP with similar affinity. However, unlike wild-type VPAC2, the deletion variant VPAC2 did not transduce VIP-elicited increases in intracellular concentrations of cAMP. It was concluded that a natural deletion of a part of the last transmembrane domain of mouse VPAC2 abrogates signaling functions. Recently, however, this group has shown a differential signaling pathway for wild-type compared to the deletion variant of VPAC2 [35] . Using production of IL-4, they reported that exogenous VIP increases IL-4 production from wild-type VPAC2 transfectants, but decreased IL-4 production when using the deletion variant VPAC2 transfectants [35] . Data also supported their conclusion that the ratio of expression of these two forms of VPAC2 contributes to the overall agonist effect and that these two VPAC2 receptor isoforms have opposing functions and can compete with each other in the production of IL-4.
In our study, we have detected two naturally occurring human 5TM isoforms of VPAC receptors that are differentially expressed in different human cell types. Several distinct modes of GPCR ligand binding have been observed in which any truncation of the GPCR protein could influence ligand binding and thus affect signaling pathways that could result in various and specific functional activities [36, 37] . Therefore, we investigated and compared the expression and response to ligand of the predicted 5TM VPAC isoforms to those of their 7TM counterpart. Showing that both 5TM and 7TM transcripts are found differentially expressed in both transformed and normal cell types suggests that expression of these proteins may have biological relevance.
We predicted from sequence analyses that the 5TM isoforms would not activate G proteins but that they may, nevertheless, transduce a signal when stimulated with ligand. As the 5TM isoforms for both VPAC1 and VPAC2 have similar structures, we used only VPAC1 to examine the functionality of these 5TM isoforms. In this regard, we investigated the ability of VIP and secretin to activate adenylate cyclase and induce cAMP production and also examined tyrosine phosphorylation following receptor stimulation. These studies revealed that the 5TM isoform has a severe inability to activate adenylate cyclase and produce cAMP. This was predicted due to deleted sequences necessary for heterotrimeric G protein interaction. Of interest was that when stimulated with secretin, the 5TM isoform actually resulted in a significant reduction in the endogenous cAMP levels (Fig. 6A ). This could occur as a result of ligandinduced activation of a phosphodiesterase [38] . Activation of phosphodiesterase resulting in decreased cAMP production has been previously described [39] . Furthermore, this effect on cAMP by secretin suggests that if phosphodiesterase is activated, it must be through a G-protein-coupled-independent mechanism. There are a number of reports of G-proteinindependent signaling mechanisms [40] [41] [42] . Indeed, despite lack of G protein binding, the 5TM isoform was able to activate tyrosine kinase activity, supporting a signaling pathway that is independent of heterotrimeric G protein activation. Indeed, previous investigators have reported tyrosine kinase-dependent, G-protein-coupled-independent signaling pathways [43] . Thus, our results suggest that a different signaling pathway(s) that involves G-protein-independent mechanisms may be associated with the 5TM isoform. Our results contrast with a previous report showing that a 5TM isoform of CCR5 had no effect on receptor activation compared to 7TM [30] ; however, this may be due to the fact that the 5TM isoform in this study continued to retain the ability to bind G proteins.
Our observation that these isoforms of VPAC1 and VPAC2 are differentially expressed in various cell types is of particular interest. It is intriguing to speculate that since these receptors have differential signaling, their differential expression, particularly in malignant cells, could have biological significance. Indeed, it is known that VPAC receptors can be overexpressed in certain cancers and that stimulation of VPAC receptors on cancer cells can increase their growth rate [44, 45] . Our findings that 5TM isoforms of VPAC1 or VPAC2 may be found in malignant cells raises the intriguing possibility that expression of the 5TM isoform on cancer cells, as it binds ligand but does not activate adenylate cyclase, may compete with the 7TM isoform, as has previously been suggested for IL-4 production with mouse VPAC2 variants [35] . Thus, further study of the expression of the 5TM isoform in various cancers is warranted. It is also very curious that in cord blood there was no evidence of a 5TM isoform of either VPAC1 or VPAC2; however, in adult human PBMCs both isoforms were clearly found, with VPAC2 isoforms requiring cell activation for optimal expression.
These data have identified and characterized the region of specific alternative splicing of the first human examples of a 5TM isoform of both VPAC1 and VPAC2. We have shown the differential expression of these splice variants in both primary human peripheral blood cells and various transformed cell lines, including malignant cancer-derived cell lines. Finally, we have demonstrated differential signaling of the 5TM isoform compared to the 7TM form. Taken together, our findings provide valuable knowledge of 5TM isoforms of VPAC receptors and suggest these have biological relevance. Further studies are currently under way to elucidate better their potential role in biological processes. 
Materials and methods
Cells
Cell lines used in this study were obtained from the American Type Culture Collection (Manassas, VA, USA). CHO Flp-In cells were purchased from Gibco (Burlington, ON, Canada). Whole blood was obtained through the Canadian Blood Services from normal volunteers after they consented to donate blood. PBMCs were isolated from whole blood using a Ficoll-Hypaque density gradient. Nonadherent cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS; Sigma, Canada) and 0.1% gentamicin. The cultures were maintained at 37°C in a humidified atmosphere of 5% CO 2 and 95% air, at a density of 10 6 cells/ml by addition of culture medium every other day. Adherent cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL), supplemented with 10% FBS and 100 units/ml each penicillin and streptomycin and grown in 5% CO 2 and 95% air at 37°C. CHO Flp-In cells were grown in HAM F-12 nutrient mixture (Gibco) containing 10% FBS and 0.125% hygromycin. The cultures were maintained at 37°C in a fully humidified atmosphere of 5% CO 2 and 95% air, at a density of 10 6 cells/ml by addition of culture medium every other day. The viability of all cells was confirmed by trypan blue exclusion (viability >96%) prior to experiments.
cDNA cloning and sequencing
For cloning of full-length VPAC1 and VPAC2, mRNAs were isolated from normal human primary cells and the Sup-T1 cell line, respectively, using the QuikPrep Micro mRNA purification kit (Amersham Pharmacia Biotech, Inc. Canada). Reverse transcription was accomplished using the First-Strand cDNA synthesis kit (Amersham Pharmacia Biotech) according to the manufacturer's directions with the exception that a mixture of three oligo(dT) primers was used as the first-strand primer containing a C, A, or G at the 3′ position [46] . PCR was performed in a Perkin-Elmer GeneAmp PCR 9700 thermocycler and reactions contained 1× Olerup SSP PCR Master Mix with 1 unit of Taq polymerase (Genovison, Inc., West Chester, PA, USA), 25 μM forward and reverse primers, and 2 μl of template cDNA described above, plus a no-template control, in 25-μl volumes. After initial denaturation at 95°C for 2 min, 35 cycles of amplification were carried out at 94°C for 1 min, 60°C for 1 min, 72°C for 1 min, with a final extension step of 7 min at 72°C. The nucleotide sequences of oligonucleotide primers used for the PCR were designed based on the published sequences (GenBank database Accession No. L13288, VPAC1, Sense F, 5′-CTCAGGG-CAGACCATGCGCCCGCCA-3′, and Antisense R, 5′-CAGACCAGGGA-GACTTCGGCTTG-3′, corresponding to, respectively, nt 82-106 and 1467-1445 of the VPAC1 receptor; and Accession No. L36566, VPAC2, Sense F, 5′-CACGCTGAGCTCGGGATGCGGA-3′, and Antisense R, 5′-AGATGACC-GAGGTCTCCGTTTG-3′, corresponding to nt 147-168 and 1477-1456, respectively). The sense and antisense primer pairs used were specific for the amplification of the full-length VPAC receptors as well as the TM5-7 domains and C-terminus regions. Following PCR amplification, 20 μl of PCR product was subjected to electrophoresis on a 1.5% agarose gel and stained with ethidium bromide. The DNA fragments obtained were purified by using the QIAquick gel extraction kit (Qiagen, Inc., Mississauga, ON, Canada) and then cloned directly into the pCR2.1-TOPO vector (Invitrogen Canada, Inc., Burlington, ON, Canada). All of the positive clones with a cDNA insert that potentially contained multitranscripts of VPAC1 and VPAC2 were sequenced by the dideoxy method using reagents (Amersham Pharmacia Biotech) with the T7 and M13 primers. The sequences for VPAC1 and VPAC2 were analyzed using the software DNASIS Max 2.0 and BLAST in the GenBank database.
Construction of stable VPAC-expressing cell lines
The cDNAs encoding both full-length wild-type human VPAC1 receptor and the 5TM variant truncated isoform were excised from the above TA cloning vectors by digestion with BglII and XbaI and inserted into the BamHI and XbaI sites of the mammalian expression vector pcDNA3.1 (Invitrogen), which contains an Xpress-tag insert. CHO cells were selected for transfection as these cells do not express VPAC1 mRNA, although VPAC2 mRNA was detected (data not shown). CHO cells were plated in 100-mm dishes (4 × 10 6 cells/dish) and transfected with 10 μg of the recombinant plasmid containing the wild-type and variant VPAC1 receptors or pcDNA3.1 empty vector by using the CaPO 4 precipitation method. Transfected cells were grown in culture medium (DMEM) supplemented with 10% (v/v) heat-inactivated FBS, 10 μg/ml gentamicin, and 1% L-glutamine in a fully humidified atmosphere of 95% air and 5% CO 2 at 37°C. Resistant cells were selected by addition of Geneticin (G418) to a final concentration of 0.5 mg/ml. After 10-15 days of selection, individual colonies were isolated under limiting dilution in 96-well microtiter plates and grown until confluence, trypsinized, and further expanded in six-well microtiter plates. The cell clones expressing the different recombinants were selected and used for subsequent studies. Alternatively, the DNA fragments encoding both 7TM and 5TM VPAC1 were double digested and subcloned into the pcDNA5/FRT vector (Invitrogen). Briefly, the HindIII-XhoI fragment from the TA vectors, which contain DNA segments that encode 7TM/5TM VPAC1, were subcloned individually into pcDNA5/FRT (Invitrogen). The resulting plasmids were cotransfected along with pOG44 into CHO Flp-In cells (Invitrogen) to induce a site-specific integration event. Stable integrants were then screened. For verification of the expression of the 7TM and 5TM human VPAC1 receptor in the transfected cells, 1 μg of purified mRNA from transfected cells was used for cDNA synthesis. RT-PCR was carried out with specific VPAC1 receptor primers and analyzed as described above.
RT-PCR for detection of VPAC transcripts
For identification of splice-variant isoforms of both VPAC1 and VPAC2 receptors in different human cells, total RNA was isolated with the TRIzol reagent (Invitrogen) according to the manufacturer's recommendations. Two micrograms of RNA was subjected to reverse transcription with the First-Strand cDNA synthesis kit (Amersham Pharmacia Biotech) according to the manufacturer's directions, with the exception that a mixture of three oligo(dT) primers was used as the first-strand primer containing a C, A, or G at the 3′ position [46] . The cDNA was amplified by either PCR or nested-PCR with the same reagents and the following primers: VPAC1, 5′-TGCTTGCC-GTCTCCTTCTTCTCT-3′ (sense) and 5′-GATCCTGGTGGTCAGACCAGG-GAGA-3′(antisense), corresponding to nt 822-844 and 1479-1455 of the VPAC1 receptor (Accession No. L13288); VPAC2, first-round PCR, 5′-GTACTGCATCATGGCCAAC-3′ (sense) and 5′-GTGGGCCTC-CCGCCGCGTCC-3′ (antisense) corresponding to nt 792-810 and 1516-1497 of the VPAC2 receptor (Accession No. L36566); and nested-PCR, 5′-CCCTAGAAGGTGCTTCCTGG-3′ (sense) and 5′-GATGTCTCTAGAT-GACCGAGGTCTCCGTTTG-3′ (antisense), corresponding to nt 870-889 and 1479-1456. The products spanned 658 (VPAC1, 7TM), 394 (VPAC1, 5TM), 610 (VPAC2, 7TM), and 388 bp (VPAC2, 5TM).
Southern blot
For confirmation of PCR products corresponding to the expected 7TM and 5TM of VPAC2 receptor transcripts, DNA fragments were separated on 1.5% agarose gel and transferred onto Nybond-N+ nylon membrane (Amersham Biosciences). Southern blotting of DNA was performed according to the protocol (PT1190-1) from Clontech Laboratories, Inc. As hybridization probes, we used the 1.46-kb full-length VPAC2 derived from Sup-T1 cells and the DNA sequence based on the published sequence (GenBank database Accession No. L136566). The DNA probes were labeled using [32P]dCTP (Amersham) by random priming using the Multiprime DNA labeling system (Amersham Pharmacia Biotech) according to the manufacturer's directions. The membrane was washed with hybridization washing buffer and then exposed to X-ray film (Hyperfilm MP).
Metabolic labeling
To show the 7TM and 5TM VPAC1 cDNA result in protein expression, we used metabolic labeling of newly synthesized proteins by 35 S-labeled amino acids as previously described [45, 46] . Briefly, 100-mm plates of confluent CHO cells transfected using the pcDNA3.1 vector were starved of cysteine (Cys) and methionine (Met) for 1 h and then incubated at 37°C in Cys-and Met-free medium (Sigma-Aldrich Chemical, Oakville, ON, Canada) containing 0.25 mCi each of 35 S-labeled Met and Cys (1175 and 1075 Ci/mmol sp act, respectively; ICN, Costa Mesa, CA, USA) for 4 h. Following incubation, cells were washed with cold PBS and lysed in ice-cold RIPA lysis buffer (1% Nonidet P-40, 0.1% SDS, 0.1% Na 3 deoxycholate, 50 mmol/L Hepes, pH 7.3, 150 mmol/ L NaCl, 2 mmol/L sodium orthovanadate, 50 μmol/L ZnCl 2 , 2 mmol/L EDTA, 50 μM/L NaF, 50 μM orthophosphate, 2 mmol/L phenylmethylsulfonyl fluoride) for 10 min on ice. The lysate was precleared twice by adding it to unconjugated protein A-Sepharose CL4 B beads (Amersham Bioscience) with rotation for 1 h. The precleared lysate was then incubated for 2 h with antiXpress antibody that had been prebound to protein A-Sepharose beads. The beads were washed and boiled in reducing sample buffer, and the 35 S-labeled proteins were separated on SDS-PAGE. The gel was fixed in 7% acetic acid for 15 min followed by soaking for 30 min in Amplify (Amersham Bioscience). The gel was dried on a Bio-Rad Model 583 gel dryer at 80°C for 2 h and allowed to expose film (Kodak BioMax MR) by autofluorography.
Cyclic AMP assay
The biological activity of 7TM and 5TM human VPAC1 receptors was assessed by their ability to elicit intracellular cAMP generation in response to VIP and secretin stimulation. In summary, the transfected Flp-In CHO cells (10 5 cells/ml in 100-μl volumes) were grown in 96-well microtiter plates overnight. To measure the cAMP accumulation, cells were then stimulated with 50 μM VIP or 50 μM secretin for 30 s at 37°C. The medium was aspirated, cells were lysed, and cAMP was quantified by using a cAMP enzyme immunoassay (EIA) system (Amersham Pharmacia Biotech), following the manufacturer's instructions.
Western blot analysis
To determine the effect of ligand stimulation on tyrosine phosphorylation, Flp-In CHO cells (3 × 10 6 ) transfected with either the 7TM or the 5TM form of VPAC1 were serum starved overnight and stimulated with 50 μM VIP or secretin for 30 min at 37°C. Following the treatment, cells were washed twice with ice-cold PBS and then lysed in RIPA lysis buffer for 10 min on ice. After centrifugation, cell lysates were mixed with SDS sample buffer and boiled. Proteins were separated by 10% SDS-PAGE and blotted onto nitrocellulose membranes. The membranes were blocked for 1 h at room temperature using Tris-buffered saline (TBS) containing 0.8% BSA (Bioshop, Burlington, ON, Canada) plus 0.045% fish gelatin (Sigma-Aldrich). The membranes were washed in TBS-Tween 20 and then incubated for 2 h with monoclonal anti-phosphotyrosine antibody (4G10; Upstate Biotechnology, Inc., Lake Placid, NY, USA), washed, and then incubated with goat antimouse IgG conjugated to horseradish peroxidase (Bio-Rad, Mississauga, ON, Canada) followed by enhanced chemiluminescence (Bioscience Corp., Baie D'Urfé, QC, Canada) used to visualize the proteins. Membranes were stripped (30 min at 50°C using 100 mM 2-mercaptoethanol and 2% SDS in 62.5 mM Tris-HCl, pH 6.9) and then reprobed using anti-β-actin (SigmaAldrich) to control for loading.
